Archives for: ‘Kim O’Connell’

Generic supplier obtains substantial reduction in damages awarded against it

Justice Jagot has allowed a generic pharmaceutical company a 30% reduction to account for risks associated with the past hypothetical cash-flows which underlie the assessment of damages in the case.  The decision is H Lundbeck A/S v Sandoz Pty Ltd [2018] FCA 1797 and is the culmination of many years’ litigation concerning Lundbeck’s patent for the antidepressant escitalopram.

Read More
Subjects:

Manner of manufacture and software-based inventions: What does it mean for an invention to involve “an improvement in the computer”?

Whether inventions relating to the use of a computer are patentable according to the ‘manner of manufacture’ test has for many years been unclear in Australia.  This uncertainty, together with inconsistencies in how the law has been applied by the courts and the Australian Patent Office (APO), were just some of the contentious issues recently considered by a full bench of five judges from the Federal Court in Encompass Corporation Pty Ltd v InfoTrack Pty Ltd (NSD 734/2018)

Read More
Subjects:

A very modest win: Generic Health gets 2% cut to Bayer’s $25 million damages

Last year, Bayer was awarded more than $25 million (plus interest and indemnity costs) against Generic Health in the first Federal Court award of damages for pharmaceutical patent infringement.  In the appeal by Generic Health, the Full Court of the Federal Court allowed Generic Health a 2% discount to the $25 million damages originally awarded. What made the FCFCA give Generic Health such a modest discount?

Read More
Subjects:

IPO 2018: Insights from the USPTO, EPO and the bench (when digital natives meet digital immigrants)

The Intellectual Property Owners Association’s 46th Annual Meeting took place in Chicago on 23-25 September 2018.  Suzy Madar from the Sydney IP team reports on the conference highlights.

Read More

United States Court of Appeals upholds PTAB decision on CRISPR Patent Interference

The interference action between the University of California (UC) and Broad Institute (Broad) has seemingly come to an end, with the United States Court of Appeals for the Federal Circuit Court (CAFC) affirming that the patent claims that had been granted to Broad in relation to its CRISPR/Cas9 gene editing patents are separately patentable from the claims of a patent application made by UC.

Read More
Subjects:

United States FDA gets serious about biosimilars

The most significant advances in medical treatments are being made with biological products.  As biological medicines are significantly more expensive than traditional small molecule drugs, upward pressure is being placed on health spending. For example, in the United States, biological medicines accounted for 40% of all prescription drugs spending and 70% of the increase in healthcare spending in the five …

Read More
Subjects:

Digital health receives funding boost from Federal Government

Australia’s digital health sector received a major boost in April this year when the Federal Government announced a $55 million cash injection to launch the new Digital Health Cooperative Research Centre (CRC) and its programs which will bring together a consortium of more than 60 health, medical technology and pharmaceutical companies, universities and research institutes operating across the health, aged …

Read More
Subjects:

Australian Plant Breeders’ Rights to be significantly strengthened

The Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Bill 2018 seeks to introduce yet further changes aimed at improving Australia’s intellectual property laws.  The proposed amendments to the Plant Breeder’s Rights Act, 1994 cover many key aspects of Australia’s plant breeders’ rights regime and are expected to have a significant impact on the agricultural sector.  For …

Read More

#BIO2018: Gene therapy, AI in healthcare, precision medicine and Diana Ross – The power of biotechnology

As we wrap up our week of insights on the biotech industry and coverage of #Bio2018, what is clear is that for many biotech innovations, the story is just beginning. From landmark developments in genetic engineering techniques, the integration of AI and digital technologies into health care products and services and the increasing investment in genomics based medicine, perhaps the …

Read More
Subjects:

Page 1 of 2212345»1020...Last »